Repositorio Institucional
Repositorio Institucional
CONICET Digital
  • Inicio
  • EXPLORAR
    • AUTORES
    • DISCIPLINAS
    • COMUNIDADES
  • Estadísticas
  • Novedades
    • Noticias
    • Boletines
  • Ayuda
    • General
    • Datos de investigación
  • Acerca de
    • CONICET Digital
    • Equipo
    • Red Federal
  • Contacto
JavaScript is disabled for your browser. Some features of this site may not work without it.
  • INFORMACIÓN GENERAL
  • RESUMEN
  • ESTADISTICAS
 
Artículo

Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model

Fuentes Mejia, Monserrat; Fallico, Maximiliano JoséIcon ; Talevi, AlanIcon ; Gavernet, LucianaIcon ; Orozco Suárez, Sandra A.; Rocha, Luisa
Fecha de publicación: 09/2025
Editorial: Frontiers Media
Revista: Frontiers in Pharmacology
ISSN: 1663-9812
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:
Farmacología y Farmacia

Resumen

Drug resistance affects 30% of patients with epilepsy. Cannabidiol (CBD)decreases the expression of drug-resistant seizures in specific syndromes.However, it is unknown if CBD prevents the development of drug-resistantcondition in epilepsy. This research was conducted to investigate ifsubchronic administration of CBD with sodium channel blockers modifies themortality associated with clonic-tonic seizures and the development of the drug-resistant phenotype induced by subchronic administration of 3-mercaptopropionic acid (3-MP) in rats. These effects were compared withthose elicited by antiseizure medications acting on the GABAA receptors. MaleWistar rats were used to evaluate CBD combined with different antiseizuremedications (phenobarbital, diazepam, valproic acid, lamotrigine andoxcarbazepine) during the repetitive administration of 3-MP. The mortalityrate and development of drug-resistant seizures were estimated.Computational experiments explored interactions between CBD and sodiumchannel blockers in the NaV1.7 receptor. Subchronic administration of CBD alonedid not modify neither the mortality rate nor the development of drug-resistantseizures. CBD combined with phenobarbital or diazepam reduced the mortalityrate and prevalence of drug-resistant seizures. In contrast, coadministration ofCBD with valproic acid or lamotrigine did not modify neither the mortality rate northe expression of drug-resistant seizures. Contrariwise, combining CBD withoxcarbazepine at ED50 increases the incidence of drug-resistant seizures.Computational experiments suggested that CBD acting on NaV1.7 interfereswith the action of sodium channel blockers and precludes their inhibitoryeffects. Our results indicate that repeated administration of CBD withGABAergic antiseizure medications, but not sodium channel blockers,decreases the mortality and prevents the development of the drug-resistantphenotype induced by repeatedly provoked severe seizures.
Palabras clave: DRUG RESISTANCE , SEIZURES , CANNABIDIOL , GABAERGIC DRUGS , SODIUM CHANNEL BLOCKERS
Ver el registro completo
 
Archivos asociados
Thumbnail
 
Tamaño: 2.350Mb
Formato: PDF
.
Descargar
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/272723
URL: https://www.frontiersin.org/articles/10.3389/fphar.2025.1644018/full
DOI: http://dx.doi.org/10.3389/fphar.2025.1644018
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Citación
Fuentes Mejia, Monserrat; Fallico, Maximiliano José; Talevi, Alan; Gavernet, Luciana; Orozco Suárez, Sandra A.; et al.; Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model; Frontiers Media; Frontiers in Pharmacology; 16; 9-2025; 1-11
Compartir
Altmétricas
 

Enviar por e-mail
Separar cada destinatario (hasta 5) con punto y coma.
  • Facebook
  • X Conicet Digital
  • Instagram
  • YouTube
  • Sound Cloud
  • LinkedIn

Los contenidos del CONICET están licenciados bajo Creative Commons Reconocimiento 2.5 Argentina License

https://www.conicet.gov.ar/ - CONICET

Inicio

Explorar

  • Autores
  • Disciplinas
  • Comunidades

Estadísticas

Novedades

  • Noticias
  • Boletines

Ayuda

Acerca de

  • CONICET Digital
  • Equipo
  • Red Federal

Contacto

Godoy Cruz 2290 (C1425FQB) CABA – República Argentina – Tel: +5411 4899-5400 repositorio@conicet.gov.ar
TÉRMINOS Y CONDICIONES